See what CeloNova is doing about COVID-19 Read More

COBRA PzF NanoCoated Coronary Stent (NCS)

A New Category of Stent

COBRA PzF NCS is the world’s first non-drug eluting, nanocoated stent that allows physicians to safely and effectively treat their patients who may benefit from a short, minimum 1-month DAPT requirement.5

Indications, Contraindications, Warnings & Precautions

Designed with
Healing in Mind

The revolutionary COBRA PzF NCS is a new nanocoated, non drug-eluting stent that allows physicians to safely and effectively treat their patients who may benefit from a short, minimum 1-month DAPT requirement.1

Designed with Healing in Mind

The revolutionary COBRA PzF NCS is a new nanocoated, non drug-eluting stent that allows physicians to safely and effectively treat their patients who may benefit from a short, minimum 1-month DAPT requirement.1

Exceptional Safety & Efficacy

In the eCOBRA all-comers study, COBRA PzF NCS demonstrated an excellent safety profile with low TLR in patients at high risk of bleeding and stent thrombosis in a real-world setting.2

“The study demonstrated good follow-up with excellent numbers…One of the numbers I was most impressed with was the need for repeat revascularization…given that its [COBRA’s] major feature is thromboresistance, 4% TLR is really quite spectacularly good.”

-Dr. Philip Urban, MD, Medical Co-Director CERC, Paris, France

Click here to watch the complete interview.

Learn About COBRA REDUCE IDE 14-Day DAPT Trial
At 270 Days

0.4%

Late Stent Thrombosis2 (Definite/Probable)

4.3%

TLR‡2

~30% OAC
  21% STEMI
  56% ACS

High Risk Patients2

N: 940 | France Multicenter | Mean Age: 73
COBRA PzF NCS indications include patients with diabetes mellitus
Learn About COBRA REDUCE IDE 14-Day DAPT Trial

Polyzene-F NanoCoating
Makes the Difference

Polyzene-F is a nano-thin surface coating that has been studied extensively in the past 20+ years, demonstrating thrombo-resistant, anti-inflammatory and rapid healing effects in preclinical studies.3-7*

Polyzene-F NanoCoating Makes the Difference

Polyzene-F is a nano-thin surface coating that has been studied extensively in the past 20+ years, demonstrating thrombo-resistant, anti-inflammatory and rapid healing effects in preclinical studies.3-7*

About PzF

Optimized Stent Performance

Polyzene-F Nano-Thin Structure

Delivery System Specifications

Balloon Specifications
Catheter Specifications

Product Ordering Information

The COBRA PzF coronary stent is FDA and CE approved and commercially available for purchase. Contact a CeloNova sales representative today.

Contact a Sales Representative
* AS DEMONSTRATED IN HUMAN AND PRECLINICAL STUDIES.
Correlation between bench testing, animal studies and humans have not been determined.
‡ Stent thrombosis defined as ARC Definite, Probable and Possible; stent thrombosis and cTLR assessed at 270 days [95% Confidence Interval ST, 0.00%, 1.29%, cTLR, 2.45%, 7.67%]
+ For more information about the COBRA REDUCE IDE trial, please visit: clinicaltrials.gov/ct2/show/NCT02594501.
  1. Levine G, Bates E, Bittl J, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients with Coronary Artery Disease. Circulation. 2016;134(10):e123-55.
  2. Maillard, L, de Labriolle, A, Brasselet, C, et al. Evaluation of the safety and efficacy of the Cobra PzF NanoCoated coronary stent in routine, consecutive, prospective, and high‐risk patients: The e‐Cobra study. Catheter Cardiovasc Interv. 2020; 1– 10. https://doi.org/10.1002/ccd.29065
  3. Koppara T, Sakakura K, Pacheco E, et al. Preclinical evaluation of a novel polyphosphazene surface modified stent. International Journal of Cardiology. 2016; 222:217-225.
  4. Mrowietz C, Franke R, Seyfert U, et al. Haemocompatibility of polymer-coated stainless steel stents as compared to uncoated stents. Clinical Hemorheology and Microcirculation. 2005; 32:89–103.
  5. Richter G, Stampfl U, Stampfl S, et al. A New Polymer Concept for Coating of Vascular Stents Using PTFEP (poly(bis(trifluoroethoxy)phosphazene) to Reduce Thrombogenicity and Late In-Stent Stenosis. Investigative Radiology. 2005; 40(4):210-218.
  6. Radeleff B, Thierjung H, Stampfl U, et al. Restenosis of the CYPER-Select, TAXUS-Express, and Polyzene-F NanoCoated Cobalt-Chromium Stents in the Minipig Coronary Artery Model. Cardiovasc Intervent Radiol. 2007.
  7. Tamburino C, Giacoppo D, Capodanno D, et al. The Rapid Evaluation of Vessel Healing after Angioplasty (REVEAL) trial. Interv.Cardiol. 2011; 3 (4): 451-460.